Central Nervous System Pharmacology

Central Nervous System Pharmacology: Key Concepts for General Medicine

Understanding how drugs interact with the central nervous system (CNS) is essential for clinicians managing neurological and psychiatric disorders. This course synthesizes the core mechanisms, therapeutic uses, and side‑effect profiles highlighted in a recent quiz on CNS pharmacology. Each section corresponds to a quiz question, providing a deeper educational narrative while incorporating SEO‑friendly keywords such as levodopa mechanism, MAO‑B inhibition, phenobarbital GABA, and sertraline selectivity.

1. Levodopa and Parkinson’s Disease

Mechanism of action: Levodopa (L‑DOPA) is a precursor of dopamine that readily crosses the blood‑brain barrier via the large neutral amino‑acid transporter. Once inside the CNS, aromatic L‑amino‑acid decarboxylase (AADC) converts levodopa to dopamine, replenishing the depleted neurotransmitter in the striatum and improving motor symptoms.

• It does not directly stimulate dopamine receptors; its effect depends on enzymatic conversion.
• Inhibition of acetylcholine release is a secondary effect, not the primary therapeutic action.
• Levodopa does not block monoamine oxidase‑B (MAO‑B); that role belongs to agents like selegiline.

Clinicians often combine levodopa with peripheral decarboxylase inhibitors (e.g., carbidopa) to prevent premature conversion and reduce peripheral side effects.

2. Selegiline and the Tyramine (Cheese) Reaction

Selegiline is a selective, irreversible inhibitor of MAO‑B at therapeutic doses. MAO‑A, primarily located in the gastrointestinal tract, metabolizes dietary tyramine. Because selegiline spares MAO‑A, tyramine is still broken down, and the classic “cheese reaction” is less likely. However, at higher doses, selegiline loses selectivity and can inhibit MAO‑A, leading to hypertensive crises when patients ingest tyramine‑rich foods.

• Selegiline does not block dopamine reuptake.
• It does not induce hepatic enzymes that increase tyramine production.
• The key pharmacologic property is its selective MAO‑B inhibition, preserving MAO‑A activity.

3. Phenobarbital vs. Benzodiazepines: GABAergic Modulation

Both phenobarbital and benzodiazepines enhance the inhibitory neurotransmitter gamma‑aminobutyric acid (GABA) at the GABAA receptor, but they differ in how they modify the ion channel:

• Phenobarbital increases the duration that the chloride channel remains open, leading to prolonged hyperpolarization.
• Benzodiazepines increase the frequency of channel opening without affecting the open‑time duration.

This distinction explains phenobarbital’s longer half‑life and its utility in status epilepticus, whereas benzodiazepines provide rapid, short‑acting seizure control.

4. Tolerance and Sedation with Benzodiazepines

When a benzodiazepine is initiated for generalized anxiety disorder, patients often experience initial drowsiness and sedation. With continued use, these acute central nervous system effects tend to diminish due to pharmacodynamic tolerance, while the anxiolytic effect may persist for a limited period before tolerance develops.

• Cognitive impairment may worsen, not improve, with chronic exposure.
• Risk of severe withdrawal increases after prolonged therapy.
• Development of tolerance to the anxiolytic effect is common, contrary to the statement that it is uncommon.

5. Sertraline: A Selective Serotonin Reuptake Inhibitor (SSRI)

Sertraline belongs to the SSRI class and selectively inhibits the serotonin transporter (SERT), increasing extracellular serotonin without significantly affecting norepinephrine reuptake. This selectivity differentiates sertraline from tricyclic antidepressants (TCAs), which block both serotonin and norepinephrine reuptake and possess anticholinergic properties.

• Sertraline does not act as a monoamine oxidase inhibitor; dietary tyramine restrictions are unnecessary.
• Its primary action does not involve enhancing GABA transmission.
• Understanding this mechanism helps clinicians anticipate side effects such as sexual dysfunction and gastrointestinal upset, which are typical of SSRIs.

6. Haloperidol‑Induced Acute Dystonia

Haloperidol is a high‑potency typical antipsychotic that exerts its therapeutic effect by strongly antagonizing dopamine D2 receptors in the mesolimbic pathway. However, blockade of D2 receptors in the nigrostriatal pathway disrupts the balance between dopaminergic and cholinergic activity, leading to extrapyramidal symptoms (EPS) such as acute dystonia.

• Haloperidol does not enhance GABAergic transmission.
• It does not inhibit acetylcholine release; rather, the relative excess of acetylcholine contributes to motor side effects.
• Partial agonism at 5‑HT2A receptors is a property of atypical antipsychotics, not haloperidol.

Prophylactic anticholinergic agents (e.g., benztropine) can mitigate these EPS.

7. Ethosuximide and Absence Seizures

Ethosuximide is the drug of choice for typical absence seizures. Its primary electrophysiologic target is the T‑type calcium channel in thalamic relay neurons. By reducing low‑threshold calcium currents, ethosuximide suppresses the rhythmic thalamocortical oscillations that generate the characteristic 3‑Hz spike‑and‑wave discharges seen on EEG.

• It does not act on NMDA‑type glutamate receptors.
• GABAA receptor modulation is not its main mechanism.
• Voltage‑gated sodium channel blockade is the primary action of drugs like carbamazepine, not ethosuximide.

8. Propofol: Rapid‑Onset General Anesthesia

Propofol produces hypnosis and rapid induction of anesthesia primarily through potentiation of the GABAA receptor. By increasing the duration of chloride channel opening, propofol enhances inhibitory neurotransmission, leading to profound neuronal hyperpolarization.

• It does not inhibit voltage‑gated calcium channels in the spinal cord.
• Opioid μ‑receptor activation is the mechanism of agents like fentanyl, not propofol.
• Unlike ketamine, propofol does not block NMDA receptors.

Its favorable pharmacokinetic profile—rapid distribution and clearance—makes propofol ideal for induction and maintenance of anesthesia, as well as for procedural sedation.

Integrating Knowledge: Clinical Application Checklist

Use this checklist to reinforce learning and support clinical decision‑making:

• Parkinson’s disease: Choose levodopa with a peripheral decarboxylase inhibitor; monitor for dyskinesias.
• MAO‑B inhibitors: Verify dose‑dependent selectivity; educate patients about tyramine when high‑dose selegiline is used.
• Seizure emergencies: Prefer phenobarbital for prolonged control; use benzodiazepines for rapid termination.
• Anxiety treatment: Anticipate early sedation that may wane; assess for tolerance and dependence.
• Depression management: Switch from TCAs to SSRIs like sertraline to reduce anticholinergic burden.
• Antipsychotic side effects: Monitor for EPS with high‑potency D2 antagonists; consider anticholinergic prophylaxis.
• Absence seizures: Prescribe ethosuximide; avoid sodium‑channel blockers unless comorbid seizure types exist.
• General anesthesia: Select propofol for rapid onset; be aware of its GABAA potentiation and dose‑dependent hypotension.

Key Take‑aways for Exam Preparation

When tackling CNS pharmacology questions, focus on the following patterns:

• Identify the primary neurotransmitter affected (dopamine, serotonin, GABA, calcium).
• Distinguish between receptor antagonism and enzyme inhibition (e.g., D2 blockade vs. MAO‑B inhibition).
• Remember the site of action—central vs. peripheral—and its clinical implications.
• Link side‑effect profiles to the drug’s mechanism (e.g., EPS from D2 antagonism, sedation from GABA potentiation).

By mastering these concepts, you will be well‑prepared for both board examinations and real‑world patient care.